Treating the untreatable
Our passion for patients in need fuels our dedication to fill the therapeutic void with hope for the future. With RNA as the basis of our discovery platform, we are able to bring therapeutic options to patients who otherwise would have none.
Our antisense therapies are designed to interact precisely with RNA, allowing us to create treatments that disrupt the disease process and change its course. With three approved best- and first-in-class medicines and 10+ in mid- or late-stage development, our therapeutic breakthroughs are poised to continue to transform the futures of patients for years to come.
For more information about QALSODY and U.S. prescribing information, visit www.QALSODY.com.
For more information about SPINRAZA and U.S. prescribing information, visit www.SPINRAZA.com.
For more information about TEGSEDI and U.S. prescribing information, visit www.TEGSEDI.com.
For WAYLIVRA prescribing information in the EU, please visit www.ema.europa.eu/en/medicines/human/EPAR/waylivra.